Sugi Predict

Sugi Predict / Compounds / Edratide

Edratide

Edratide

SCHEMBL29355439

CC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)NCC(=O)O)[C@@H](C)CC)[C@@H](C)CC

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ IL23R Q5VWK5 1/20 0.62
▸ MC4R P32245 4/20 0.61
▸ MC5R P33032 2/20 0.61
▸ MC3R P41968 2/20 0.61
▸ MC1R Q01726 2/20 0.61
▸ NPY1R P25929 1/20 0.60
▸ NPY2R P49146 1/20 0.60
▸ NPY4R P50391 1/20 0.60
▸ NPY5R Q15761 1/20 0.60
▸ CXCR4 P61073 4/20 0.59
▸ C5AR1 P21730 1/20 0.57
▸ KEAP1 Q14145 1/20 0.55
▸ GLP1R P43220 5/20 0.55
▸ CXCL8 P10145 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29901070 0.97 MC4R (0.65) IL23RMC4RMC5RMC3RMC1R
SCHEMBL30607498 0.87 NPY2R (0.70) IL23RMC4RMC5RMC3RMC1R
SCHEMBL31683320 0.86 NPY2R (0.73) NPY1RNPY2RNPY4RNPY5RCXCR4
SCHEMBL30906368 0.86 NPY2R (0.65) NPY1RNPY2RNPY4RNPY5RCXCR4
SCHEMBL31657611 0.86 IL23R (0.66) IL23RMC4RMC5RMC3RMC1R
SCHEMBL30648464 0.85 IL23R (0.64) IL23RMC4RMC5RMC3RMC1R
SCHEMBL30618038 0.85 IL23R (0.67) IL23RMC4RMC5RMC3RMC1R
SCHEMBL30906424 0.85 NPY2R (0.70) NPY1RNPY2RNPY4RNPY5RCXCR4
SCHEMBL31688313 0.85 NPY1R (0.63) NPY1RNPY2RNPY4RNPY5RCXCR4
SCHEMBL30775451 0.84 MC4R (0.67) IL23RMC4RMC5RMC3RMC1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735431-A2 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. (US) 2026-05-06 — — EP claimed
EP-4674484-A2 THIENOPYRROLE COMPOUNDS Gilead Sciences, Inc. (US) 2026-01-07 — — EP claimed
US-20250387510-A1 ADENO-ASSOCIATED VIRUS FORMULATIONS SPARK THERAPEUTICS, INC. (US) 2025-12-25 — — US claimed
US-20250367267-A1 TREATING AUTOIMMUNE DISEASES WITH INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR LIGAND CONJUGATED TO AN AGENT LIRUM THERAPEUTICS INC (US) 2025-12-04 — — US claimed
US-20250339399-A1 SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) 2025-11-06 — — US claimed
EP-4638765-A2 ADENO-ASSOCIATED VIRUS FORMULATIONS Spark Therapeutics, Inc. (US) 2025-10-29 — — EP claimed
EP-4291562-B1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES INC (US) 2025-09-10 — — EP claimed
EP-4547265-A1 TREATING AUTOIMMUNE DISEASES WITH INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR LIGAND CONJUGATED TO AN AGENT Lirum Therapeutics, Inc. (US) 2025-05-07 — — EP claimed
CN-119698288-A Treatment of autoimmune diseases with insulin-like growth factor 1 receptor ligands conjugated to agents 利鲁姆治疗公司 2025-03-25 — — CN claimed
US-20250049780-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2025-02-13 — — US claimed
EP-4267559-A1 SUBSTITUTED INDOLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2023-11-01 — — EP claimed
CN-116783202-A Thienopyrrole compounds 吉利德科学公司 2023-09-19 — — CN claimed
US-20230270734-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2023-08-31 — — US claimed
US-11661431-B2 Thienopyrrole compounds GILEAD SCIENCES, INC. (US) 2023-05-30 — — US claimed
WO-2023039464-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2023-03-16 — — WO claimed
US-20220389034-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2022-12-08 — — US claimed
WO-2022221642-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-10-20 — — WO claimed
WO-2022173722-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-08-18 — — WO claimed
WO-2022140325-A1 6-SUBSTITUTED INDOLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-06-30 — — WO claimed
WO-2022140326-A1 SUBSTITUTED INDOLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-06-30 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230270734-A1 THIENOPYRROLE COMPOUNDS SSB, TPMT, LCP2 IL23R 1245/4885MC4R 438/4885MC5R 227/4885
US-20250049780-A1 THIENOPYRROLE COMPOUNDS SSB, TPMT, LCP2 IL23R 1245/4885MC4R 438/4885MC5R 227/4885
US-20250339399-A1 SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM S100A8, TP53, AQP1 IL23R 733/4885MC4R 1739/4885MC5R 1470/4885
US-11661431-B2 Thienopyrrole compounds SSB, TPMT, LCP2 IL23R 1245/4885MC4R 438/4885MC5R 227/4885
US-20220389034-A1 THIENOPYRROLE COMPOUNDS SSB, TPMT, LCP2 IL23R 1245/4885MC4R 438/4885MC5R 227/4885
US-20250387510-A1 ADENO-ASSOCIATED VIRUS FORMULATIONS CACNA1D, CACNA1S, SCN1A IL23R 1269/4885MC4R 1547/4885MC5R 2885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback